Durvalumab 50 MG/ML

Phase 2

Durvalumab 50 MG/ML is one of 11 therapeutic programs targeting Small Cell Lung Cancer ( SCLC ). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Small Cell Lung Cancer ( SCLC )Recruiting

Small Cell Lung Cancer ( SCLC )Phase 2

Recruiting

Competition

Competitive Landscape

13 competitors in Small Cell Lung Cancer ( SCLC )

#DrugCompanyPhaseTrials

Tecentriq

Roche

Phase 3

3 2

Paraplatin

AAvyxa

Phase 3

1 3

Vepesid

AAvyxa

Phase 3

1 4

Obrixtamig

Boehringer Ingelheim

Phase 3

1 5

Taxol

Teva

Preclinical

1 6

Zepzelca

Jazz Pharmaceuticals

Preclinical

1 7

Camptosar

Pfizer

Preclinical

1 8

Hycamtin

MMeitheal

Preclinical

1 9

PF-08634404

Pfizer

Preclinical

1 10

Durvalumab 50 MG/ML

AAlliance Foundation Trials, LLC.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 2Recruiting

Small Cell Lung Cancer ( SCLC )

NCT07149363

Clinical

Trials by Indication[1]

Small Cell Lung Cancer ( SCLC )1 trial

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

Recruiting·AAlliance Foundation Trials, LLC.·Phase 2·NCT07149363·65 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Durvalumab 50 MG/ML. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Durvalumab 50 MG/ML. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Alliance Foundation Trials, LLC. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: AAlliance Foundation Trials, LLC.

Durvalumab 50 MG/ML

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Small Cell Lung Cancer ( SCLC )1 trial

References

Drug Info

Quick Facts

Related News